Denali Therapeutics, Biogen begin phase 2 study of BIIB122 to treat Parkinson’s disease
Denali Therapeutics (NASDAQ:DNLI) and partner Biogen (NASDAQ:BIIB) said on Tuesday dosing had begun in the global Phase 2b study testing their drug, BIIB122 (DNL151), as compared to placebo in about 640 participants with early-stage Parkinsonâs disease.
The trial, dubbed Luma, is being conducted in people with early-stage Parkinsonâs disease between the age of 30 and 80.

Denali and Biogen are co-developing and co-commercializing BIIB122.
The drug is an inhibitor of LRRK2, a potential novel target expected to impact the underlying biology and slow the progression of Parkinsonâs disease.
In mid-March, the company said its Chief Operating Officer Alexander Schuth would add the Chief Financial Officer role to his current responsibilities.